File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
  • Basic View
  • Metadata View
  • XML View
TitleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
 
AuthorsSeto, WK2
Tanaka, Y1
Wong, DKH2
Lai, CL2
Shinkai, N1
Yuen, JCH2
Tong, T2
Fung, J2
Hung, IFN2
Yuen, MF2
 
KeywordsHBcrAg
HBsAg
Linearized HBsAg
Seroclearance
Serology
 
Issue Date2013
 
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
CitationHepatology International, 2013, v. 7 n. 1, p. 98-105 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-012-9354-7
 
AbstractBackground: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.
 
ISSN1936-0533
2013 Impact Factor: 2.468
 
DOIhttp://dx.doi.org/10.1007/s12072-012-9354-7
 
DC FieldValue
dc.contributor.authorSeto, WK
 
dc.contributor.authorTanaka, Y
 
dc.contributor.authorWong, DKH
 
dc.contributor.authorLai, CL
 
dc.contributor.authorShinkai, N
 
dc.contributor.authorYuen, JCH
 
dc.contributor.authorTong, T
 
dc.contributor.authorFung, J
 
dc.contributor.authorHung, IFN
 
dc.contributor.authorYuen, MF
 
dc.date.accessioned2012-09-05T05:31:43Z
 
dc.date.available2012-09-05T05:31:43Z
 
dc.date.issued2013
 
dc.description.abstractBackground: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4 months. The median age at HBsAg seroclearance was 50 years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2 months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r = 0.095, p = 0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and >12 months after HBsAg seroclearance (p = 0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p = 0.581) and HBcrAg (p = 0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. © 2012 Asian Pacific Association for the Study of the Liver.
 
dc.description.natureLink_to_subscribed_fulltext
 
dc.identifier.citationHepatology International, 2013, v. 7 n. 1, p. 98-105 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-012-9354-7
 
dc.identifier.citeulike10463261
 
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-012-9354-7
 
dc.identifier.epage105
 
dc.identifier.hkuros213662
 
dc.identifier.issn1936-0533
2013 Impact Factor: 2.468
 
dc.identifier.scopuseid_2-s2.0-84875241425
 
dc.identifier.spage98
 
dc.identifier.urihttp://hdl.handle.net/10722/163465
 
dc.languageeng
 
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
 
dc.publisher.placeUnited States
 
dc.relation.ispartofHepatology International
 
dc.subjectHBcrAg
 
dc.subjectHBsAg
 
dc.subjectLinearized HBsAg
 
dc.subjectSeroclearance
 
dc.subjectSerology
 
dc.titleEvidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Seto, WK</contributor.author>
<contributor.author>Tanaka, Y</contributor.author>
<contributor.author>Wong, DKH</contributor.author>
<contributor.author>Lai, CL</contributor.author>
<contributor.author>Shinkai, N</contributor.author>
<contributor.author>Yuen, JCH</contributor.author>
<contributor.author>Tong, T</contributor.author>
<contributor.author>Fung, J</contributor.author>
<contributor.author>Hung, IFN</contributor.author>
<contributor.author>Yuen, MF</contributor.author>
<date.accessioned>2012-09-05T05:31:43Z</date.accessioned>
<date.available>2012-09-05T05:31:43Z</date.available>
<date.issued>2013</date.issued>
<identifier.citation>Hepatology International, 2013, v. 7 n. 1, p. 98-105</identifier.citation>
<identifier.issn>1936-0533</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/163465</identifier.uri>
<description.abstract>Background: Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. Methods: We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linearized HBsAg (CLEIA prototype) in 329 CHB patients (72.0% male) after HBsAg seroclearance was documented by a conventional HBsAg assay. Results: The median interval between presentation and HBsAg seroclearance was 69.4&#160;months. The median age at HBsAg seroclearance was 50&#160;years. Assays for serum HBV DNA, HBcrAg, and linearized HBsAg were performed at a median time interval of 11.2&#160;months after HBsAg loss. Linearized HBsAg and HBcrAg were detectable in 85 (25.8%) and 69 (21%) patients, respectively, and one or both serologic markers were detectable in 133 patients (40.4%). Serum HBV DNA was detectable in only 7 patients (2.1%). There was no correlation between linearized HBsAg and HBcrAg levels (r&#160;=&#160;0.095, p&#160;=&#160;0.924). The incidences of detectable linearized HBsAg and HBcrAg did not differ between patient samples taken at 6-12 and &gt;12&#160;months after HBsAg seroclearance (p&#160;=&#160;0.146 and 0.079, respectively). Among patients with detectable serologic markers, median levels of linearized HBsAg (p&#160;=&#160;0.581) and HBcrAg (p&#160;=&#160;0.951) did not significantly change with time after HBsAg seroclearance. Conclusion: Using novel HBcrAg and linearized HBsAg assays, viral serologic activity after HBsAg seroclearance was demonstrated in more than 40% of CHB patients. These tests have potential applications in diagnosing and prognosticating CHB patients with HBsAg seroclearance. &#169; 2012 Asian Pacific Association for the Study of the Liver.</description.abstract>
<language>eng</language>
<publisher>Springer New York LLC. The Journal&apos;s web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0</publisher>
<relation.ispartof>Hepatology International</relation.ispartof>
<subject>HBcrAg</subject>
<subject>HBsAg</subject>
<subject>Linearized HBsAg</subject>
<subject>Seroclearance</subject>
<subject>Serology</subject>
<title>Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay</title>
<type>Article</type>
<description.nature>Link_to_subscribed_fulltext</description.nature>
<identifier.doi>10.1007/s12072-012-9354-7</identifier.doi>
<identifier.scopus>eid_2-s2.0-84875241425</identifier.scopus>
<identifier.hkuros>213662</identifier.hkuros>
<identifier.spage>98</identifier.spage>
<identifier.epage>105</identifier.epage>
<publisher.place>United States</publisher.place>
<identifier.citeulike>10463261</identifier.citeulike>
</item>
Author Affiliations
  1. Nagoya City University
  2. The University of Hong Kong